Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Peakadilly nv biopharmaceutical firm created

18.10.2004


The Flanders Interuniversity Institute for Biotechnology (VIB) and Ghent University have started up a new biopharmaceutical company named Peakadilly nv. Peakadilly will develop and market a new generation of molecular diagnostics − so-called protein bio-markers − using innovative proteomics technology developed by the research group under the direction of Joël Vandekerckhove. The markers can be used in the development of medicines, making the process much more efficient, effective and economical. The bio-markers will also enable doctors to detect diseases sooner and, because many medicines work effectively only with a limited group of patients, doctors will also be able to verify whether a particular medicine will work for certain patients. Peakadilly will be led by Koen Kas, who has been closely involved in the development of the technology platform.



Health care tailored to the patient

Today, it takes an average of 800 million euro and about 12 years to develop a new drug. Among other things, the time-consuming and expensive clinical studies test the safety and effectiveness of a potential medicine. Frequently, the studies indicate that the drug is not really effective at all, or only for a small number of patients. At present, nothing exists for measuring whether a candidate drug is truly effective during development. Bio-markers can bridge this gap and thus substantially lower the development costs and time.


Bio-markers will also make it possible to target therapies specifically to the patients for whom they are successful. Most drugs in the field of oncology, for example, help only a limited number of patients. Bio-markers will enable the appropriate therapy to be selected for the patient − a step toward patient-specific medicine. The bio-markers will also enable earlier detection of life-threatening diseases like cancer.

The impact of bio-markers for the patient − and, indirectly, for the social security system − will be profound. Whereas bio-markers are suitable and desired in every disease field, Peakadilly will initially focus on applications in oncology − operating at the interface of diagnostics and therapeutics.

The product of innovative proteomics technology

Proteins are responsible for all life processes in our cells − regulating the digestion of our food, communication between cells, and so on. Defects in (the activity of) particular proteins are at the basis of many diseases (such as diseases of the muscles and cancer), and the development of medicines focuses on restoring or positively affecting the proteins’ activity. Proteomics − the study of the proteome, or proteins in their entirety – is of crucial importance for this. The technology enables one to uncover all the differences between the proteome of a sick person and that of a healthy person, and between the proteome of a patient who reacts positively to a drug and of a patient who is not helped by it.

Proteomics can also provide insight into the origin and progression of diseases. The analysis of the effect of a drug on the proteome enables researchers to understand which protein(s) the drug acts upon. Until recently, however, there was no efficient way to study the proteome systematically. Pioneering research under the direction of Joël Vandekerckhove (Scientific Director of a VIB research department at Ghent University) has led to a technology that, for the first time, enables thousands of proteins to be analyzed in a systematic way.

Peakadilly will apply this proteomics technology to identify specific proteins and protein profiles that are related to a disease or the activity of a candidate drug. Then, with this knowledge, Peakadilly will develop the bio-markers. An advantage of the technology is that it can be used on blood. Blood samples are routinely used, of course, for diagnosing a number of (infectious) diseases − but the current techniques obtain only a limited amount of information from the sample. Peakadilly’s bio-markers should make it possible to detect diseases more quickly (giving medical treatment a much greater chance of success) and to gear the therapy to the patient more effectively.

Start-up

Since the invention of the technology in 2001, the research team and VIB’s technology transfer team have been working on the development of a patented technology and product platform. When the technology and its product potential were presented in an early stage to a select group of (bio)pharmaceutical firms, the need for such a technology and products proved to be so large that R&D collaborations at a value of around 2 million euro were quickly established with 3 well-known firms.

These collaborations made it possible to house the technology in a new start-up enterprise: Peakadilly. The new company will be led by Koen Kas, who was a member of VIB’s tech-transfer team and fully involved in the development of the platform. The new CEO holds a doctorate in the bio-medical sciences, is an instructor at Ghent and Harvard Universities, and has previously held management positions in research at Tibotec, Virco and Galapagos.

Peakadilly will start out in the VIB bio-incubator, located in the Technology Park of Ghent University in Zwijnaarde. Among others, 4 VIB employees − all with extensive company experience − are transferring to Peakadilly to give the company a flying start. This start-up team will then be enlarged further. In addition, the company maintains its good relationship with the VIB department at Ghent University, where the technology was first developed and where it is being further developed with a team of 12 researchers.

Rudy Dekesyer | alfa
Further information:
http://www.vib.be

More articles from Life Sciences:

nachricht A new technique isolates neuronal activity during memory consolidation
22.06.2017 | Spanish National Research Council (CSIC)

nachricht CWRU researchers find a chemical solution to shrink digital data storage
22.06.2017 | Case Western Reserve University

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

Im Focus: Optoelectronic Inline Measurement – Accurate to the Nanometer

Germany counts high-precision manufacturing processes among its advantages as a location. It’s not just the aerospace and automotive industries that require almost waste-free, high-precision manufacturing to provide an efficient way of testing the shape and orientation tolerances of products. Since current inline measurement technology not yet provides the required accuracy, the Fraunhofer Institute for Laser Technology ILT is collaborating with four renowned industry partners in the INSPIRE project to develop inline sensors with a new accuracy class. Funded by the German Federal Ministry of Education and Research (BMBF), the project is scheduled to run until the end of 2019.

New Manufacturing Technologies for New Products

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

A new technique isolates neuronal activity during memory consolidation

22.06.2017 | Life Sciences

Plant inspiration could lead to flexible electronics

22.06.2017 | Materials Sciences

A rhodium-based catalyst for making organosilicon using less precious metal

22.06.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>